These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32468080)

  • 1. Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
    He G; Xie X; Siddik ZH
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1129-1140. PubMed ID: 32468080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.
    Xie X; He G; Siddik ZH
    Mol Cancer Res; 2017 Mar; 15(3):328-339. PubMed ID: 28031409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.
    Voland C; Bord A; Péleraux A; Pénarier G; Carrière D; Galiègue S; Cvitkovic E; Jbilo O; Casellas P
    Mol Cancer Ther; 2006 Sep; 5(9):2149-57. PubMed ID: 16985047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
    Siddik ZH; Mims B; Lozano G; Thai G
    Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.
    Fiebiger W; Olszewski U; Ulsperger E; Geissler K; Hamilton G
    Clin Transl Oncol; 2011 Jan; 13(1):43-9. PubMed ID: 21239354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Ratner ES; Zhu YL; Penketh PG; Berenblum J; Whicker ME; Huang PH; Lee Y; Ishiguro K; Zhu R; Sartorelli AC; Lin ZP
    Br J Cancer; 2016 Mar; 114(7):777-86. PubMed ID: 26964031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
    BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H; Park C; Yao M
    Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
    Bhatt M; Ivan C; Xie X; Siddik ZH
    Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.